Microsoft Corporation (MSFT): Surface Pro Gets Panned

Page 1 of 2

Microsoft Corporation (NASDAQ:MSFT) has been looking to move into a new direction in the last few months, heavily marketing its new Windows 8 operating system, and stepping into its own in-house hardware excursion with the release of the Surface RT tablet last fall. Then, the company has put a lot of energy into hyping its Surface Pro, or as the company calls it, the Surface with Windows 8 Professional. However, with the Surface Pro making it way into the market, some techies are giving their reviews – and the device seems to be getting panned more than praised.

Oh, it’s not all bad. Microsoft Corporation (NASDAQ:MSFT) did get its share of positive comments about the hardware, the speed of the OS and the general performance. However, many of the negative comments surrounded a lack of memory, the weight of the device and very short battery life.  The Surface Pro does run the full Windows 8 OS, which Microsoft claims makes it the first tablet to run a full operating system. The device comes in 64- and 128-gigabyte versions with wi-fi only compatibility. The 64-GB device sells for $899, but the keyboard/cover is sold separately for $120.

Microsoft Corporation (NASDAQ:MSFT)Walt Mossberg of AllThingsD wrote, “It ran all the software I threw at it – both the new type and the old desktop type – speedily and well. But the Pro has some significant downsides, especially as a tablet … It’s too hefty and costly and power-hungry to best … Apple’s full-size iPad. It is also too difficult to use in your lap. It’s something of a tweener – a compromised tablet and a compromised laptop.” He added that the Surface Pro’s battery lasted just four hours – half as long as an iPad from Apple Inc. (NASDAQ:AAPL).

What are some other comments from these tech writers?

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!